£5
The minority funding round was led by BGF to support global expansion and platform development.
BGF
Venture CapitalBGF is one of the largest and most experienced growth capital investors operating across the UK and Ireland.
Recent investments
£11.0M
The funding round was supported by BGF, Parkwalk Advisors, DBW, and BBI to drive clinical and product development.
"This investment is a strong endorsement of our team, technology, and vision. The early clinical data from our temporary device has given us real momentum, and with this funding, we’re excited to advance our permanent pacing platform, an innovation that could redefine how heart failure is treated."
£15.0M
The Nottingham-based scheduling infrastructure provider has raised £15m from growth capital investor BGF.
"Cronofy is a stand-out tech success story that has achieved global recognition in its vertical for having the most reliable embedded scheduling infrastructure. Its ROI for a range of different customer types and size, including enterprise, is compelling. It has a customer centric, product first growth strategy that has already generated 60% of its sales from the more mature US market. We look forward to partnering with this impressive management team who have a proven track record in solving problems for customers and scaling tech businesses."
£9.0M
Phlux Technology secures £9m Series A funding from BGF to scale production and expand product lines.
BGF led the Series A round with participation from existing backers including Octopus Ventures, Northern Gritstone, and Foresight.
"This funding comes at a pivotal moment as demand for high-speed optical communication systems is growing enormously. By developing world-class, high-performance infrared sensors, we are enabling industries to push the boundaries of connectivity, efficiency, and security by removing a technology bottleneck that has persisted for over 20 years."
£58.0M
General Catalyst led the financing alongside a syndicate of new and existing investors to support the developer of antibody-based therapeutics.
"KnotBodies represent a potential breakthrough biologic drug modality, delivering greater potency, selectivity, and durability. We believe they will provide transformational new therapeutic options for ion channel- and GPCR-driven diseases across a wide range of therapeutic areas with a remaining high unmet medical need. The calibre of our international investor syndicate validates our approach, and I would like to welcome our new investors to Maxion and thank our existing investors for their continued support."
